E

New developments in Multiple Myeloma

We take a look at several key developments in myeloma on the antibody and cell therapy front.

February 11, 2019
E

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019
E

A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019
E

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019
E

JPM19 Day 3 Highlights

Commentary on some up and coming biotechs in the oncology space

January 9, 2019
E

JPM19 Highlights from Day 2

Insights and commentary from the second day at #JPM19

January 8, 2019
E

JPM18 Healthcare Day 3 Highlights

Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco

January 10, 2018
E

How Obsidian could revolutionise CAR T cell therapy in solid tumours

A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours

January 10, 2018
E

JPM19 Highlights from Day 1

Insights and commentary from the first day of JPM19

January 7, 2019
E

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018
E

Highlights of JPM18 Healthcare Day 2

Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 9, 2018
E
San Francisco Trolley Car

Highlights of JPM18 Healthcare Conf Day 1

Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 8, 2018
E
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
E
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017
E

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
E
SF Streetcar at Pine St

JPM17 Healthcare Conference Day 3 Highlights

Commentary on Wednesday at JPM17 in San Francisco

January 11, 2017
E
San Francisco Streetcar in Rain

Highlights of JPM17 Healthcare Conference Day 2

Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco

January 10, 2017
E
San Francisco Streetcar

Highlights of JPM17 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.

January 9, 2017
E

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017
E

Promising new agents to watch out for in Chronic Lymphocytic Leukemia

A look at some promising agents in new product development emerging in early CLL trials

January 6, 2017
E

The Changing CLL Landscape Part 1

How are recently approved novel therapies impacting the CLL landscape and where are we going next?

January 5, 2017
E

Does Polatuzumab Vedotin have Potential in Lymphomas?

A look at the latest data for a CD79b targeted ADC in lymphomas

January 4, 2017
E

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017
E

Seattle Genetics vadastuximab talirine and liver toxicities in AML

An in-depth look at the sudden and unexpected announcement underlying the clinical hold for Seattle Genetics anti-CD33 ADC Vadastuximab Talirine in AML.

December 28, 2016
E

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018
E

A New Race to Market in Advanced Prostate Cancer

Two biotech companies are in a race to market for a novel target in advanced prostate cancer.

January 19, 2016
E

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco

January 13, 2016
E

Highlights of #JPM16 Healthcare Conference Day 2

Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.

January 12, 2016
E

Highlights of #JPM16 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.

January 11, 2016
E

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016
E

Potential of Rociletinib in T790M negative NSCLC

Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.

January 28, 2015
E

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
E

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015
E

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015
E

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015
E

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015
E

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015
E

Targeting the unmet medical need in GvHD

Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.

January 5, 2015
E

Update on CO-1686 and AZD9291 race to market in T790M NSCLC

Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.

January 15, 2014
E

Can Agios score a winner with their anti-cancer metabolism molecules?

Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?

January 13, 2014
E

Insights on Foundation Medicine and how molecular testing will transform cancer research

Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.

January 8, 2014
E

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E

Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?

The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?

January 6, 2014